Horst Kunz


Affiliation: University of Mainz
Country: Germany


  1. Glaffig M, Palitzsch B, Stergiou N, Schüll C, Strassburger D, Schmitt E, et al. Enhanced immunogenicity of multivalent MUC1 glycopeptide antitumour vaccines based on hyperbranched polymers. Org Biomol Chem. 2015;13:10150-4 pubmed publisher
  2. Palitzsch B, Gaidzik N, Stergiou N, Stahn S, Hartmann S, Gerlitzki B, et al. A Synthetic Glycopeptide Vaccine for the Induction of a Monoclonal Antibody that Differentiates between Normal and Tumor Mammary Cells and Enables the Diagnosis of Human Pancreatic Cancer. Angew Chem Int Ed Engl. 2016;55:2894-8 pubmed publisher
    ..We synthesized MUC1-glycopeptide vaccines and analyzed their structure-activity relationships in immunizations; a monoclonal antibody that specifically distinguishes between human normal and tumor epithelial cells was thus generated. ..
  3. Shi L, Cai H, Huang Z, Sun Z, Chen Y, Zhao Y, et al. Synthetic MUC1 Antitumor Vaccine Candidates with Varied Glycosylation Pattern Bearing R/S-configured Pam3 CysSerLys4. Chembiochem. 2016;17:1412-5 pubmed publisher